MINNEAPOLIS, May 08, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies...
Successfully Delivered First Development Candidate to Biogen; $8 Million Payment EarnedEstablished a Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt,...
Contacts MEDIA RELATIONS Anna Rozenich, Senior Director, Enterprise Communications The Baldwin Group 630.561.5907 | Anna.rozenich@baldwin.com INVESTOR RELATIONS Bonnie Bishop, Executive...
HOUSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense...
NAPLES, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Beasley Broadcast Group, Inc. (Nasdaq: BBGI) (“Beasley” or the “Company”), a multi-platform...
NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
-- Generated $27.2 million in net revenue from sales of LUMRYZ™ ---- Through March 31, greater than 2,800 patients enrolled...
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat...
Clinical Results and Potential New Drug Application Submission Expected in the Second Half of 2024 Contacts Investors & Media: David...
Contacts Investor Relations ir@affirm.com Media press@affirm.com Affirm Holdings, Inc. (NASDAQ: AFRM), the payment network that empowers consumers and helps merchants...
– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma –– Evaluating the...
Full commercial launch of OLPRUVA at the end of January 2024, with market access growing to ~75% of covered lives...
- THRIVE VRDN-001 global phase 3 clinical trial in active thyroid eye disease (TED) completed and exceeded its target for...
VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Village Farms International, Inc. (“Village Farms” or the “Company”) (NASDAQ: VFF)...
KING OF PRUSSIA, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading...
U.S. FDA Approval of Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy; Commercial...
NEEDHAM, Mass., May 8, 2024 /PRNewswire/ -- Tripadvisor, Inc. (NASDAQ: TRIP) issued its first quarter 2024 earnings press release which is...
– Dose expansion initiated in TNG908 phase 1/2 clinical trial – – Dose expansion expected to initiate in TNG462 phase...
MINNEAPOLIS, May 8, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer,...
STAMFORD, Conn., May 08, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe...
Annual award recognizes five extraordinary women in the waste and recycling industry for their leadership and achievements BANNOCKBURN, Ill., May...
– NDA filing for revumenib in R/R KMT2Ar acute leukemia granted Priority Review under RTOR; PDUFA action date set for September...
Topline data from Phase 2b trial of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis on...
8.3% Improvement in Adjusted EBITDA on 8.0% Lower Revenue Operating Income of $5.2 Million Versus Operating Loss of $0.7 Million...
First Quarter Net Income and Adjusted EBITDA Increased 188% and 49% Full Year Net Income Guide Increased, Net Revenue and...
MURRAY, Utah, May 08, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1” or the “Company”), a leading provider...
Contacts Shane Kleinstein 720-875-5432 Qurate Retail, Inc. ("Qurate Retail") (Nasdaq: QRTEA, QRTEB, QRTEP) today reported first quarter 2024 results(1). “Our...
Contacts Shane Kleinstein 720-875-5432 Qurate Retail, Inc. ("Qurate Retail") (Nasdaq: QRTEA, QRTEB, QRTEP) today reported first quarter 2024 results(1). “Our...
Contacts Shane Kleinstein 720-875-5432 Qurate Retail, Inc. ("Qurate Retail") (Nasdaq: QRTEA, QRTEB, QRTEP) today reported first quarter 2024 results(1). “Our...
More Than 200 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site...
OSLO, Norway, May 8, 2024 /PRNewswire/ -- Opera Limited (NASDAQ: OPRA), one of the world's major browser developers and a leading...
SAN DIEGO and CALGARY, AB, May 8, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company...
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the...
SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company...
LOUISVILLE, Colo., May 8, 2024 /PRNewswire/ - (TSX: CWEB) (OTCQX: CWBHF), Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the...
Contacts Investor Relations: Chance Pipitone ir@newfortressenergy.com Media Relations: Ben Porritt press@newfortressenergy.com (516) 268-7403 New Fortress Energy Inc. (Nasdaq: NFE) (“NFE”...
ZTALMY® (ganaxolone) Q1 2024 net product revenue of $7.5 million representing strong growth of 125% versus Q1 2023 Increased full...
YOQNEAM, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- MIND C.T.I. LTD. – (NasdaqGM:MNDO), a leading provider of convergent end-to-end prepaid/postpaid...
Net sales of $927 million Adjusted EBITDA of $186 million Organic adjusted EBITDA margin of 20.1% Operating cash flows of...
Continued market adoption of VOWST® with approximately 1,411 patient enrollment forms received, approximately 1,083 new patient starts, and net sales...
